Lv61
2968 积分 2024-04-22 加入
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
3个月前
已完结
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
3个月前
已完结
Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics
5个月前
已完结
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
6个月前
已完结
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
7个月前
已完结
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
7个月前
已完结
Gastric Cancer
8个月前
已完结
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
11个月前
已完结
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
11个月前
已完结
[Mechanism and management of cancer chemotherapy-induced gastrointestinal mucosa damage]
1年前
已完结
皖公网安备34019202002308
